Skip to main content

Schizophrenia & Psychotic Disorders

Schizophrenia & Psychotic Disorders
Early intervention in schizophrenia may not actually slow or stop a patient’s mental decline, despite a common belief that it will, researchers reported in The American Journal of Psychiatry online.
Bipolar Disorders
Christoph U. Correll, MD, discusses the results of the ENLIGHTEN‑2 study, which compared weight gain and cardiometabolic side effects in patients taking olanzapine and patients taking olanzapine plus samidorphan.
Schizophrenia & Psychotic Disorders
Successfully treating reduced motivation, or avolition, in patients with schizophrenia has a positive effect on other negative symptoms, according to a study published online in Schizophrenia Bulletin.
Bipolar Disorders
The US Food and Drug Administration (FDA) has accepted Alkermes’ New Drug Application (NDA) for ALKS 3831, a combination of olanzapine and samidorphan, the company announced.
Schizophrenia & Psychotic Disorders
Long-term use of antipsychotics by patients with schizophrenia does not increase the risk of hospitalization for comorbid conditions—and is actually associated with substantially decreased mortality, according to a study in World Psychiatry.
Schizophrenia & Psychotic Disorders
Having a dog in the household during childhood may significantly decrease the risk of schizophrenia later in life, suggests a study published online in PLOS One.
Alzheimer's Disease, Dementia & Cognitive Disorders
Cognitive aging appears to occur more rapidly in people with psychotic disorders, compared with peers without such disorders, according to a study that followed 445 people for 2 decades after their first psychotic disorder hospitalization.
Schizophrenia & Psychotic Disorders
The US Food and Drug Administration (FDA) has approved lumateperone (Caplyta), a novel antipsychotic from Intra-Cellular Therapies, Inc., for the treatment of schizophrenia in adults.
General Psychiatry
A recently published systematic review and meta-analysis found what proportion of people who experienced psychosis with cannabis use later transitioned to schizophrenia?
Schizophrenia & Psychotic Disorders
Pimavanserin, currently approved by the US Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, reduced the risk of psychosis relapse 2.8-fold in patients with dementia.
Schizophrenia & Psychotic Disorders
In patients with schizophrenia and viral hepatitis, the second-generation antipsychotic paliperidone was associated with a reduced risk of liver damage.
Back to Top